Anthracycline (specialist)
Daunorubicin
Brand names: Cerubidin
Adult dose
Dose: Per AML "7+3" protocol — 60–90mg/m² IV days 1–3
Route: IV
Frequency: Per protocol
Clinical pearls
- AML induction ("3" of 7+3) — BSH AML guidelines / ESMO
- UKONS extravasation — dexrazoxane
- Baseline echo / MUGA
Contraindications
- Severe myocardial impairment
- Cumulative anthracycline limit reached
- Severe hepatic/renal impairment
- Hypersensitivity
Side effects
- Cardiotoxicity (cumulative limit ~550mg/m²)
- Myelosuppression
- Mucositis
- Alopecia
- Nausea/vomiting
- Vesicant — extravasation (dexrazoxane antidote)
- Red urine
Interactions
- Trastuzumab (cardiotoxicity)
- Live vaccines
Monitoring
- FBC
- LVEF
- Cumulative dose
- Extravasation
Reference: BNF; BSH AML; ESMO; UKONS; SmPC; https://bnf.nice.org.uk/drugs/daunorubicin-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
Pathways
- Acute Myeloid Leukaemia Presentation · BSH; NICE — NG146
- Tumour Lysis Syndrome · Cairo-Bishop; BSH; NICE — Best Practice
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158